



Genomic Health, Inc.
Investor Relations Department
301 Penobscot Dr.
Redwood City, CA 94063
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: GHDX

| | |
|---------------|----------------------------|
| Last Trade: | 65.33 |
| Trade Time: | 4:00 PM ET Oct 12, 2018 |
| Change: | 0.00 (0.000%) |
| Day Range | N/A - N/A |
| 52-Week Range | 26.54 - 72.83 |
| Volume | 26 |


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Oct 9, 2018*
[New NCCN Breast Cancer Guidelines Elevate Oncotype DX Breast Recurrence Score® as the Only Preferred Multi-gene Test to Predict Chemotherapy Treatment](#)
- Sep 28, 2018*
[New Published Data and Recent Positive Private Payor Coverage Decisions Underscore Value and Utility of the Oncotype DX Genomic Prostate Score® \(GPS™\) Test](#)
- Sep 7, 2018*
[German Health Technology Assessment Body \(IQWiG\) Concludes Only Oncotype DX® has Sufficient Evidence to Guide Breast Cancer Adjuvant Chemotherapy Decisions Based on Landmark TAILORx Study Results](#)
- Aug 2, 2018*
[Genomic Health Announces Second Quarter 2018 Financial Results and Reports Recent Business Progress](#)
- Jul 26, 2018*
[Genomic Health to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 2, 2018](#)

Financials & Filings [\[View all \]](#)

- Mar 14, 2018*
[Annual Report \(10-K\)](#)
- Apr 27, 2018*
[Proxy Statement \(DEF 14A\)](#)
- Aug 7, 2018*
[Quarterly Report \(10-Q\)](#)
- May 9, 2018*
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2017*
[Quarterly Report \(10-Q\)](#)